Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13316486 | 0.87 | POLB (0.49) | ALOX12LMNASMN1; SMN2HPGDKDM4E | |
| SCHEMBL12501215 | 0.81 | ALOX12 (0.53) | ALOX12LMNASMN1; SMN2HPGDKDM4E | |
| SCHEMBL16290005 | 0.79 | ALOX12 (0.53) | ALOX12LMNASMN1; SMN2HPGDKDM4E | |
| SCHEMBL9506369 | 0.79 | ALOX12 (0.56) | ALOX12LMNASMN1; SMN2HPGDKDM4E | |
| SCHEMBL6860661 | 0.78 | ALOX12 (0.54) | ALOX12LMNASMN1; SMN2HPGDKDM4E | |
| SCHEMBL16328702 | 0.78 | ALOX12 (0.54) | ALOX12LMNASMN1; SMN2HPGDKDM4E | |
| SCHEMBL31115536 | 0.78 | ALOX12 (0.54) | ALOX12LMNASMN1; SMN2HPGDKDM4E | |
| SCHEMBL19646456 | 0.78 | ALOX12 (0.54) | ALOX12LMNASMN1; SMN2HPGDKDM4E | |
| SCHEMBL13272906 | 0.76 | POLB (0.39) | ALOX12LMNASMN1; SMN2HPGDKDM4E | |
| SCHEMBL4587864 | 0.76 | ALOX12 (0.47) | ALOX12LMNASMN1; SMN2HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160311-A1 | Fungicidal Azolopyrimidines, Process for Their Preparation and Their Use For Controlling Harmful Fungi, and Also Compositions Comprising Them | BASF SE (DE) | 2010-06-24 | — | — | US | disclosed |
| US-20100092483-A1 | Compositions monovalent for CD40L binding and methods of use | DOMANTIS LIMITED | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092483-A1 | Compositions monovalent for CD40L binding and methods of use | CD40LG, CD40, FCGR1A | ALOX12 3835/4885LMNA 2948/4885SMN1; SMN2 2392/4885 |
| US-20100160311-A1 | Fungicidal Azolopyrimidines, Process for Their Preparation and Their Use For Controlling Harmful Fungi, and Also Compositions Comprising Them | G6PD, CYP51A1, ERG28 | ALOX12 2737/4885LMNA 2477/4885SMN1; SMN2 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.